LB Pharmaceuticals to Participate in Upcoming March Investor Events
Rhea-AI Summary
LB Pharmaceuticals (Nasdaq: LBRX) announced management will present at two investor events in March 2026: the Leerink 2026 Global Healthcare Conference on March 11, 2026 at 1:40 p.m. ET and the Stifel 2026 Virtual CNS Forum on March 17, 2026 at 2:30 p.m. ET.
A live webcast and archived replay will be available in the Investors > Events section of the company website at https://lbpharma.us/.
Positive
- None.
Negative
- None.
News Market Reaction – LBRX
In the Mar 5 session, LBRX declined 3.48%, reflecting a moderate negative market reaction. Argus tracked a trough of -9.8% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Inducement option grant | Neutral | -0.5% | Options granted to new General Counsel under Nasdaq inducement rules. |
| Feb 05 | Private placement financing | Positive | +12.7% | Announced $100M private placement to fund LB-102 Phase 2 and operations. |
| Jan 26 | Phase 2 trial initiation | Positive | -6.4% | Initiated Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar I depression. |
| Jan 21 | Executive appointment | Positive | +0.7% | Appointed experienced General Counsel to support CNS-focused strategy. |
| Jan 12 | Inducement equity grants | Neutral | +4.0% | Reported stock option grants to two new senior hires under inducement plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has focused on financings, clinical program expansion, and leadership hires. Price reactions have mostly aligned with the apparent tone, with one notable divergence on a clinical trial initiation headline.
Over the last few months, LB Pharmaceuticals has reported several corporate and development milestones. A $100.0 million private placement on Feb 5, 2026 supported advancement of LB-102 and saw the stock rise, while initiation of the Phase 2 ILLUMINATE-1 bipolar depression trial on Jan 26, 2026 coincided with a pullback. Management hires and inducement grants in January–February 2026 drew modest market responses. Today’s investor conference participation fits into this pattern of steady corporate and investor-relations activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases, today announced that management will present and participate in the following upcoming investor conferences:
Leerink 2026 Global Healthcare Conference
Date: Wednesday, March 11, 2026
Time: 1:40 p.m. ET
Stifel 2026 Virtual CNS Forum
Date: Tuesday, March 17, 2026
Time: 2:30 p.m. ET
A live webcast of the presentations will be available on the “Investors” section under the “Events” section of the Company’s website at https://lbpharma.us/ where a replay of the webcasts will be archived.
About LB Pharmaceuticals
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive treatment of major depressive disorder, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
Media and Investor Contact
Ellen Rose
erose@lbpharma.us
